scholarly journals Vitrectomy and external drainage of subretinal fluid containing high concentration of vascular endothelial growth factor for advanced coats disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Fukutaro Mano ◽  
Itsuka Matsushita ◽  
Hiroyuki Kondo ◽  
Shoko Utamura ◽  
Chiori Kondo ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Case Series ◽  
Subretinal Fluid ◽  
Multivariable Logistic Regression Analysis ◽  
Vascular Endothelial ◽  
High Concentration ◽  
External Drainage ◽  
Coats Disease ◽  
Endothelial Growth Factor

AbstractThis study investigated the surgical outcomes of Coats disease and the role of external drainage (XD) of subretinal fluid (SRF). The study is a multicenter retrospective interventional case series of 26 consecutive eyes of 26 patients who underwent surgeries for advanced Coats disease with retinal detachment. Main outcomes measured were: 1) comparison of complete SRF resolution with or without XD, and 2) variables that were associated with functional postoperative best-corrected visual acuity (BCVA) defined as BCVA of 0.1 or better, 3) intraocular vascular endothelial growth factor (VEGF) levels. Complete SRF resolution was achieved in all 14 eyes in which XD had been performed and in 75% of 12 eyes in which XD had not been performed (P = .03). Multivariable logistic regression analysis revealed that initial BCVA was the only variable associated with functional postoperative BCVA (odds ratio 3.24, 95% CI 0.93–11.33; P = .04). Markedly elevated VEGF levels were noted in the SRF compared with those in the vitreous humor (49,760 ± 52,990 vs. 707 ± 611 pg/mL, P = .03). XD seems to provide better anatomical success than without XD in the treatment of advanced Coats disease as XD could effectively eliminate substantial amount of VEGF in the SRF.

scholarly journals Vitrectomy and External Drainage of Subretinal Fluid Containing High Concentration of Vascular Endothelial Growth Factor for Advanced Coats Disease

2021 ◽  
Author(s):  
Fukutaro Mano ◽  
Itsuka Matsushita ◽  
Hiroyuki Kondo ◽  
Shoko Utamura ◽  
Chiori Kondo ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Case Series ◽  
Subretinal Fluid ◽  
Multivariable Logistic Regression Analysis ◽  
Vascular Endothelial ◽  
High Concentration ◽  
External Drainage ◽  
Coats Disease ◽  
Endothelial Growth Factor

Abstract This study investigated the surgical outcomes of Coats disease and the role of external drainage (XD) of subretinal fluid (SRF). The study is a multicenter retrospective interventional case series of 26 consecutive eyes of 26 patients who underwent surgeries for advanced Coats disease with retinal detachment. Main outcomes measured were: 1) comparison of complete SRF resolution with or without XD, and 2) variables that were associated with functional postoperative best-corrected visual acuity (BCVA) defined as BCVA of 0.1 or better, 3) intraocular vascular endothelial growth factor (VEGF) levels. Complete SRF resolution was achieved in all 14 eyes in which XD had been performed and in 75% of 12 eyes in which XD had not been performed (P =.03). Multivariable logistic regression analysis revealed that initial BCVA was the only variable associated with functional postoperative BCVA (odds ratio 3.24, 95% CI 0.93–11.33; P =.04). Markedly elevated VEGF levels were noted in the SRF compared with those in the vitreous humor (49,760 ± 52,990 vs. 707 ± 611 pg/mL, P =.03). XD seems to provide better anatomical success than without XD in the treatment of advanced Coats disease as XD could effectively eliminate substantial amount of VEGF in the SRF.

scholarly journals Vascular endothelial growth factor in Coats’ disease

2013 ◽  
Vol 92 (3) ◽  
pp. e225-e228 ◽  
Author(s):  
Qi Zhao ◽  
Xiao-Yan Peng ◽  
Feng-Hua Chen ◽  
Yong-Peng Zhang ◽  
Lian Wang ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Vascular Endothelial ◽  
Coats Disease ◽  
Endothelial Growth Factor

scholarly journals Assessment of Vascular Endothelial Growth Factor in Fresh versus Frozen Platelet Rich Plasma

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Nada Hosny ◽  
Fikry Goubran ◽  
Basma BadrEldin Hasan ◽  
Noha Kamel
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Calcium Gluconate ◽  
Platelet Rich Plasma ◽  
Vascular Endothelial ◽  
High Concentration ◽  
Significant Difference ◽  
Growth Factor Release ◽  
Endothelial Growth Factor ◽  
Vegf Release

Platelet rich plasma (PRP) is hemoconcentration with platelets concentration above baseline values and high concentration of many growth factors. The aim of this study was to assess freezing effect on vascular endothelial growth factor (VEGF) release from PRP using two different activation methods to simplify its use in different clinical applications. PRP was prepared using two-centrifugation steps method from 12 qualified blood donors. VEGF concentrations were measured in fresh PRP and after freezing/thawing for one and three weeks with two methods of activation using (i) calcium gluconate and (ii) calcium gluconate and thrombin. Platelets count was significantly increased compared to baseline whole blood values in all fresh and frozen PRP samples (p value was <0.05). No significant difference was found between VEGF concentrations after activating fresh and frozen-thawed PRP samples for one and three weeks by calcium alone or calcium with thrombin, and also no significant difference was found when freezing period was extended from one to three weeks. Our results showed that platelets count does not correlate with variable levels of VEGF. PRP could be prepared once and preserved frozen for at least three weeks for the next treatment sessions and activation with thrombin addition to calcium will not augment the growth factor release.

scholarly journals Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia

2018 ◽  
Vol 24 (7) ◽  
pp. 1056-1060 ◽  
Author(s):  
Grażyna Gadomska ◽  
Alicja Bartoszewska-Kubiak ◽  
Joanna Boinska ◽  
Karolina Matiakowska ◽  
Katarzyna Ziołkowska ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Essential Thrombocythemia ◽  
Leukemia Virus ◽  
Growth Factor Receptor ◽  
Platelet Derived Growth Factor ◽  
Vascular Endothelial ◽  
High Concentration ◽  
Endothelial Growth Factor ◽  
Calr Mutation

The aim of the study was to evaluate selected angiogenic factors in patients with essential thrombocythemia (ET) depending on JAK2V617F, calreticulin gene (CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations. Sixty ET patients and 20 healthy volunteers were enrolled in the study. The following tests were performed: vascular endothelial growth factor- A (VEGF-A), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1),soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), platelet-derived growth factor( PDGF-BB), and stromal-derived factor-1α (SDF-1α). We observed an increased PDGF-BB level in patients with ET compared to the controls. Patients with CALR mutation had significantly higher concentration of PDGF-BB and lower concentration of SDF-1α than patients with JAK2V617F mutation. High concentration of PDGF-BB and low concentration of SDF-1α in patients with CALR(+) ET may indicate a contribution of these chemokines in disturbed Ca2+ metabolism in platelets.

scholarly journals Management of acute submacular hemorrhage using intravitreal injection of tissue plasminogen activator and gas: A case series

2020 ◽  
Vol 8 ◽  
pp. 2050313X2097033
Author(s):  
Athanasios Karamitsos ◽  
Vasileios Papastavrou ◽  
Tsveta Ivanova ◽  
David Cottrell ◽  
Kevin Stannard ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Visual Acuity ◽  
Growth Factor ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Case Series ◽  
Recombinant Tissue Plasminogen Activator ◽  
Vascular Endothelial ◽  
Tissue Plasminogen ◽  
Endothelial Growth Factor

The objective of this case series is the evaluation of the efficacy and visual outcomes after displacement of subretinal hemorrhage using intravitreal injection of recombinant tissue plasminogen activator, expansile gas, and in some cases an anti-vascular endothelial growth factor agent. A case series of 28 eyes of 28 patients (16 men and 12 women with age range 67–95 years) suffering from subretinal hemorrhage (duration range 1–15 days) caused by age-related macular degeneration or retinal macroaneurysm is presented. All the patients were treated with intravitreal injection of recombinant tissue plasminogen activator and gas and some of them received an anti-vascular endothelial growth factor agent between January 2013 and December 2016. The outcomes assessed were visual acuity (preoperatively 1 week, and 1 month postoperatively) with respect to duration and dimension of hemorrhage, displacement of hemorrhage, and possible complications of the procedure. Successful displacement of hemorrhage was achieved in 25 patients (89.3%), 18 of 28 patients had significant improvement in visual acuity 1 week after the treatment, and 22 of 28 patients had significant improvement in visual acuity 1 month after the treatment. The mean improvement of all patients with anatomical displacement of the hemorrhage in visual acuity was 0.7 ± 0.5 (LogMAR) in 1 month. Two patients developed vitreous hemorrhage after the procedure and one retinal detachment. Visual outcome a month after therapy displayed week correlation with duration, diameter, and thickness of hemorrhage. The results lead to the conclusion that intravitreal treatment of recombinant tissue plasminogen activator and expansible gas with or without injection of anti-vascular endothelial growth factor agent is effective in improving visual acuity and displacing submacular hemorrhage secondary to age-related macular degeneration and retinal macroaneurysm. The best functional outcomes can be expected in patients regardless of the size and duration of the hemorrhage.

Sign in / Sign up

Export Citation Format

Share Document